Somerset Therapeutics Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Somerset Therapeutics Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $5.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Somerset Therapeutics Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $5.0M Trade | TransData Nexus

Somerset Therapeutics Limited

Indian Pharmaceutical Exporter · Corticosteroids Specialist · $5.0M Total Trade · DGFT Verified

Somerset Therapeutics Limited is an Indian pharmaceutical exporter with a total trade value of $5.0M across 4 products in 3 therapeutic categories. Based on 150 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Dexamethasone ($2.2M), Tobramycin ($1.5M), Sulfamethoxazole ($616.2K).

Somerset Therapeutics Limited — Export Portfolio & Destination Treemap

Somerset Therapeutics Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Somerset Therapeutics Limited? — Company Overview & Market Position

Somerset Therapeutics Limited, formerly known as Recon Pharma Private Limited and Wintac Limited, was established in 1987 as a partnership firm and incorporated on August 23, 1990, in Bangalore, Karnataka, India. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical formulations, including injectables, ophthalmic solutions, and oral dosage forms. Its manufacturing facility is located in Boodihal Village, Nelamangala, Bangalore, Karnataka, India.

Somerset Therapeutics Limited is a private company with an authorized capital of ₹50.00 crore and a paid-up capital of ₹31.60 crore. The company employs approximately 620 professionals. It is a subsidiary of Veego Pharma LLC, USA, and is promoted by Dr. Veerappan Subramanian, a seasoned pharmaceutical scientist and entrepreneur with over fifty years of experience in the generic pharmaceutical industry.

What Does Somerset Therapeutics Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Dexamethasone$2.2M 2

Product Portfolio — Top 4 by Export Value

Somerset Therapeutics Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dexamethasone	Corticosteroids	$2.2M	44	1.2%	10
2	Tobramycin	Antibiotics	$1.5M	62	3.9%	7
3	Sulfamethoxazole	Advanced Antibiotics	$616.2K	22	3.1%	7
4	Trimethoprim	Advanced Antibiotics	$616.2K	22	2.3%	10

Somerset Therapeutics Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $5.0M. The top category is Corticosteroids (44.3% of portfolio), followed by Antibiotics (30.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Somerset Therapeutics Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

The company's state-of-the-art manufacturing facility in Boodihal Village, Nelamangala, Bangalore, Karnataka, India, is approved by several international regulatory agencies, including the US FDA, ANSM (French Regulatory), TGA (Australian Regulatory), Health Canada, Pharmacy & Poison Board (Kenya), and NAFDAC (Nigeria). The facility specializes in the production of small and large volume parenterals, sterile ophthalmic preparations, and other pharmaceutical specialties catering to niche segments.

3Key Leadership

The leadership team at Somerset Therapeutics Limited includes:

Dr. K. Paranjothy: Non-Executive Chairman and Independent Director. With over 40 years of experience in the pharmaceutical industry, Dr. Paranjothy has expertise in formulation development, quality assurance, and production. He has also served as a visiting professor and published research in national and international journals.

Mr. R.A. Thirumoorti: Non-Executive Independent Director.

Mr. Murali K. P.: Whole-time Director.

Mr. Jai Velusamy: Executive Director and Chief Operating Officer of the plant.

Mohanambal Paramasivam Gounder: Director.

Krupendra V. S.: Chief Financial Officer.

CS - Jinal Jain: Company Secretary.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Somerset Therapeutics Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Somerset Therapeutics Limited has established a significant presence in regulated markets, particularly in the United States. The company's manufacturing facility has been approved by the US FDA and has been USFDA-compliant since 2013, with the most recent audit conducted in February 2020 for general Good Manufacturing Practices (GMPs) and pre-approvals. Additionally, the facility holds approvals from other international regulatory agencies, including the French Regulatory Authority (ANSM), the Australian Therapeutic Goods Administration (TGA), Health Canada, the Pharmacy & Poison Board of Kenya, and the National Agency for Food and Drug Administration & Control (NAFDAC) of Nigeria.

2Emerging Markets

Somerset Therapeutics Limited has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facility holds approvals from regulatory agencies in several countries, such as the Pharmacy & Poison Board of Kenya and NAFDAC in Nigeria, facilitating access to these regions. While specific details regarding WHO prequalification are not available, the company's adherence to international GMP standards and regulatory approvals positions it favorably for market penetration in these emerging regions.

3Geographic Strategy

Somerset Therapeutics Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Somerset Therapeutics Limited's manufacturing facility is registered with the US FDA and has been USFDA-compliant since 2013. The facility was most recently audited by the agency in February 2020 for general GMPs and pre-approvals. The company's export data indicates that its top products, such as Dexamethasone and Tobramycin, are significant contributors to its export value, highlighting the importance of maintaining FDA compliance for continued market access.

2WHO & EU GMP

Specific information regarding WHO prequalification and EU GMP certificates for Somerset Therapeutics Limited is not available. However, the company's manufacturing facility holds approvals from other international regulatory agencies, including the French Regulatory Authority (ANSM) and the Australian Therapeutic Goods Administration (TGA), indicating adherence to international GMP standards.

3CDSCO & Indian Regulatory

Somerset Therapeutics Limited's manufacturing facility is approved by the Central Drugs Standard Control Organisation (CDSCO) in India, as evidenced by its compliance with international GMP standards and regulatory approvals. The company's export data indicates that it exports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, to various international markets. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not available.

Somerset Therapeutics Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Somerset Therapeutics Limited operates in a competitive landscape, with several pharmaceutical companies offering similar products in the injectables and ophthalmic segments. While specific market share data is not available, the company's export data indicates that its top products, such as Dexamethasone and Tobramycin, are significant contributors to its export value, suggesting a competitive position in these therapeutic categories. The company's adherence to international GMP standards and regulatory approvals positions it favorably in the market.

2Key Differentiators

Somerset Therapeutics Limited's key differentiators include its state-of-the-art manufacturing facility approved by multiple international regulatory agencies, including the US FDA, ANSM, TGA, Health Canada, Pharmacy & Poison Board (Kenya), and NAFDAC (Nigeria). The company's focus on high-quality pharmaceutical formulations, including injectables, ophthalmic solutions, and oral dosage forms, and its commitment to innovation and customer satisfaction further distinguish it in the market.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Somerset Therapeutics Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Somerset Therapeutics Limited demonstrates a strong track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $5.0 million USD and 150 shipments across four products in three therapeutic categories. The company's manufacturing facility holds approvals from multiple international regulatory agencies, indicating reliability and adherence to quality standards. The concentration of its export portfolio on the top five products suggests a focused approach, though it also indicates potential risks associated with market fluctuations affecting these products.

2Certifications to Verify

Importers should verify the following certifications when considering Somerset Therapeutics Limited as a supplier:

US FDA Approval: Confirm the manufacturing facility's registration and compliance status with the US FDA.

EU GMP Certificate: Verify the facility's compliance with EU GMP standards.

Frequently Asked Questions — Somerset Therapeutics Limited

How many pharmaceutical products does Somerset Therapeutics Limited export from India?

Somerset Therapeutics Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Dexamethasone ($2.2M), Tobramycin ($1.5M), Sulfamethoxazole ($616.2K), Trimethoprim ($616.2K). Total export value is $5.0M.

What is Somerset Therapeutics Limited's total pharmaceutical export value?

Somerset Therapeutics Limited's total pharmaceutical export value is $5.0M, based on 150 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Somerset Therapeutics Limited cover?

Somerset Therapeutics Limited exports across 3 therapeutic categories. The largest are Corticosteroids (44.3%, 1 products), Antibiotics (30.9%, 1 products), Advanced Antibiotics (24.8%, 2 products).

Get Full Somerset Therapeutics Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.